Effect of left ventricular diastolic function of psoriasis: Psöriazisin sol ventrikül diyastolik fonksiyonlarına etkisi

Dursun Çayan Akkoyun; Şeref Alpsoy; Gamze Erfan; Mehmet Emin Yanık; Aydın  Akyüz

doi:10.5455/GMJ-30-161164

Authors

Dursun Çayan Akkoyun Namık Kemal University, Faculty of Medicine, Department of Cardiology, Tekirdağ, Turkey
Şeref Alpsoy Namık Kemal University, Faculty of Medicine, Department of Cardiology, Tekirdağ, Turkey
Gamze Erfan Namık Kemal University, Faculty of Medicine, Department of Dermatology, Tekirdağ, Turkey
Mehmet Emin Yanık Namık Kemal University, Faculty of Medicine, Department of Dermatology, Tekirdağ, Turkey
Aydın Akyüz Namık Kemal University, Faculty of Medicine, Department of Cardiology, Tekirdağ, Turkey

DOI:

https://doi.org/10.5455/GMJ-30-161164

Keywords:

Diastolic, Doppler, echocardiography, heart failure, psoriasis

Abstract

The objective of our study was to evaluate the diastolic left heart functions of patients with no known cardiovascular disease via tissue Doppler imaging method. 50 psoriasis patients along with 30 healthy individual controls were included in the study. When the psoriasis group was compared with the control group, a decrease in left ventricular early filling time (71.8±14.9 versus 81±13.8, P<0.05) and increase in atrial filing [67.5 (44-93) versus 60 (46-96), P<0.05] as well as decrease in E/A ratio [1.14 (0.64–1.8) versus 1.27 (0.74–1.67), P<0.05] were observed in psoriasis patients; whereas a significant increase was not observed in the deceleration time [184 (102 - 261) versus 172 (146 - 261), P>0.05]. Whereas isovolumetric relaxation time was determined to be longer [95 (55 - 121) versus 89 (39 - 114), P<0.05] in a statistically significant manner in the psoriasis group. When the psoriasis patients were compared with the control group, septal E’ [10.1 (6 – 17) versus 11 (7 – 16)] and septal E’/A’ [0.9 (0.55 – 2) versus 1.42 (0.53 – 2.67)] along with lateral E’ [11 (6 – 19) versus 14 (8 – 20)] and lateral E’/A’ [1.09 (0.62 – 2.67) versus 1.76 (0.73 – 2.5)] were determined to be lower (P<0.05). Septal A’ was determined to be higher in the psoriasis group. Our study has put forth the relationship between psoriasis and the deterioration of the functions in left ventricular diastolic functions.

Metrics

Metrics Loading ...

References

Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med 2009;122(12):1150.e1-9.

Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370(9583):263-71.

Biyik I, Narin A, Bozok MA, Ergene O. Echocardiographic and clinical abnormalities in patients with psoriasis. J Int Med Res 2006;34(6):632-9.

Tsuda S, Maeyama Y, Yamamoto N, Sasai Y, Yoshida K. Secondary amyloidosis complicating arthropathic psoriasis. Clin Exp Dermatol 1996 ;21(2):141-4.

Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35.

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.

Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005;5(2):124-39.

Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150 Suppl 67:11-23.

Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999;41(3 Pt 2):7-12.

Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289(2):194- 202.

Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment and lattice system physician’s global assessment. J Am Acad Dermatol 2004;51(4):563-9.

Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaquetype psoriasis. Dermatology 2005;210(3):194-9.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelinesand Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr 2005;18(12):1440-63.

Zachariae H. Pathologic findings in internal organs in psoriasis. Int J Dermatol 1994;33(5):323-6.

Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and majör adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2013 4;2(2):e000062.

Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd. Biology of tumor necrosis factoralpha implications for psoriasis. Exp Dermatol 2004;13(4):193-222.

Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. CircRes 1997; 81(4):627-35.

Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22(16):1374-450.

Saricaoglu H, Güllülü S, Bülbül Baskan E, Cordan J, Tunali S. Echocardiographic findings in subjects with psoriatic arthropathy. J Eur Acad Dermatol Venereol 2003;17(4):414- 7.

Gonzalez-Juanatey C, Amigo-Diaz E, Miranda-Filloy JA, Testa A, Revuelta J, Garcia-Porrua C, et al. Lack of echocardiographic and Doppler abnormalities in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Semin Arthritis Rheum 2006;35(5):333-9.